Skip to main content
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Clin Immunol. 2015 Mar 8;158(1):1–7. doi: 10.1016/j.clim.2015.02.014

Figure 3. Reduction in the number of CCR4+ T cells correlates with decreased numbers of IL-31-expressing T cells.

Figure 3

(a) PBMCs from pruritic and non-pruritic advanced CTCL samples were stained with fluorophore-conjugated monoclonal antibodies against surface-bound CD3, CD8, CD26, CCR4 and intracellular IL-31 and further analyzed by flow cytometry. Representative plots show pre-gated cells on CD3+/CD8- (upper row) and CD3+/CD8-/CD26- (lower row).

(b) PBMCs from pruritic advanced stage CTCL samples were obtained before and after the first treatment with mogamulizumab. PBMCs were then stained with fluorophore-conjugated monoclonal antibodies against surface-bound CD3, CD8, CD26, CCR4 and intracellular IL-31 and further analyzed by flow cytometry. Representative plots show pre-gated cells on CD3+/CD8-.